Статья

Vaccine- and natural infection-induced mechanisms that could modulate vaccine safety

R. Kostoff, D. Kanduc, A. Porter, Y. Shoenfeld, D. Calina, M. Briggs, D. Spandidos, A. Tsatsakis,
2021

A degraded/dysfunctional immune system appears to be the main determinant of serious/fatal reaction to viral infection (for COVID-19, SARS, and influenza alike). There are four major approaches being employed or considered presently to augment or strengthen the immune system, in order to reduce adverse effects of viral exposure. The three approaches that are focused mainly on augmenting the immune system are based on the concept that pandemics/outbreaks can be controlled/prevented while maintaining the immune-degrading lifestyles followed by much of the global population. The fourth approach is based on identifying and introducing measures aimed at strengthening the immune system intrinsically in order to minimize future pandemics/outbreaks. Specifically, the four measures are: 1) restricting exposure to virus; 2) providing reactive/tactical treatments to reduce viral load; 3) developing vaccines to prevent, or at least attenuate, the infection; 4) strengthening the immune system intrinsically, by a) identifying those factors that contribute to degrading the immune system, then eliminating/reducing them as comprehensively, thoroughly, and rapidly as possible, and b) replacing the eliminated factors with immune-strengthening factors. This paper focuses on vaccine safety. A future COVID-19 vaccine appears to be the treatment of choice at the national/international level. Vaccine development has been accelerated to achieve this goal in the relatively near-term, and questions have arisen whether vaccine safety has been/is being/will be compromised in pursuit of a shortened vaccine development time. There are myriad mechanisms related to vaccine-induced, and natural infection-induced, infections that could adversely impact vaccine effectiveness and safety. This paper summarizes many of those mechanisms. © 2020 The Author(s)

Цитирование

Похожие публикации

Документы

Источник

Версии

  • 1. Version of Record от 2021-04-27

Метаданные

Об авторах
  • R. Kostoff
    Research Affiliate, School of Public Policy, Georgia Institute of Technology, Gainesville, VA 20155, United States
  • D. Kanduc
    Department of Biosciences, Biotechnologies, and Biopharmaceutics, University of Bari, Bari, 70125, Italy
  • A. Porter
    School of Public Policy, Georgia Institute of Technology, Atlanta, GA 30332, United States
  • Y. Shoenfeld
    Search Technology, Inc., Peachtree CornersGA 30092, United States
  • D. Calina
    Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer, 5265601, Israel
  • M. Briggs
    I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation, Sechenov University, Moscow, Russian Federation
  • D. Spandidos
    Department of Clinical Pharmacy, University of Medicine and Pharmacy of Craiova, Craiova, 200349, Romania
  • A. Tsatsakis
    Independent Consultant, Roscommon, MI 48653, United States
Название журнала
  • Toxicology Reports
Том
  • 7
Страницы
  • 1448-1458
Издатель
  • Elsevier Inc.
Тип документа
  • Review
Тип лицензии Creative Commons
  • CC
Правовой статус документа
  • Свободная лицензия
Источник
  • scopus